Our Story

We combine our deep technological expertise in plant biotech, pharmaceutical production, and clinical development, to create pharmaceutical candidates for the highly unmet medical needs.

BaiyaPharming™ platform has the flexibility to produce biopharmaceutical products of interest within weeks, compared to the conventional process of taking months to years. This results in our process being faster and lower in cost for the research and development of products, such as cosmetic raw materials, diagnostic test kit materials, including those for the complex therapeutics treating cancer and infectious diseases.  

We have been scaling up our platform from scratch to hatch within our tiny laboratory since its founding in 2018. Currently, we have established a cGMP facility in Bangkok, Thailand to produce the clinical materials of our plant-produced proteins, with the capacity of a production of COVID-19 vaccine up to 5 million doses per month. 

Over the years, the collaboration of our team’s expertise in plant biotechnology, biopharmaceutical production and clinical development has driven our company towards achieving a broad portfolio of trademarked biologic candidates, advancing and strengthening our pipeline. Our visions are to be a global leader and front runner of innovation and excellence using the plant-based technology platform. We aim to change people’s lives by leading the biotech ecosystem forward by being agile, highly-networked and committed to the core values.

Our Key Strategies

Baiya Phytopharm – MP Solution –
BGF Plantrix

To align with the specific strategic objectives of the company, Baiya Phytopharm organizes itself into three independent entities that own management structure with technological support from Baiya Phytopharm: MP Solution and BGF Plantrix.

Our Story